Study of DR-01 for adults with aplastic anemia
Part of Blood & lymphatic clinical trials.
This trial is testing an experimental medicine called Dibotatug (DR-01) for adults with aplastic anemia, a condition where the bone marrow stops making enough blood cells. It aims to see if the drug is safe and can help improve blood cell counts, especially for people whose disease has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of severe aplastic anemia (SAA) or non-severe aplastic anemia that requires transfusions.
- Previously received immunosuppressive therapy (such as ATG or cyclosporine) for at least 3 months.
- If you have severe aplastic anemia, your disease must have not responded to treatment (refractory) or come back after a period of improvement (relapsed).
- If you have non-severe aplastic anemia, you must need regular blood or platelet transfusions.
- You must not have had a bone marrow transplant before, and you must not have certain inherited bone marrow failure syndromes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs to help your bone marrow make more blood cells if you have aplastic anemia and cannot have a stem cell transplant or standard immune therapy. It might improve blood counts and reduce the need for transfusions.
This trial tests whether a new combination of medicines can help treat severe aplastic anemia (SAA) or a related type (TD-NSAA). It uses a drug that helps your body make more platelets, along with immunosuppressants, and may offer an alternative if a bone marrow transplant isn't possible.
This trial studies using a donor's blood stem cells (from bone marrow or blood) for a transplant in people with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if using a mix of both types of cells is better than just blood cells alone.
This Phase 1 trial tests a “lower-intensity” chemotherapy plan followed by a stem cell transplant from a related half-match donor for severe aplastic anemia that has returned or did not respond to prior medicines. It aims to see if this approach is safe and works well enough to help your blood counts recover.
This trial compares two standard treatments for severe aplastic anemia (a condition where the bone marrow stops making enough blood cells). One treatment is a stem cell transplant from a donor, and the other is a drug therapy that suppresses the immune system. The goal is to see which works better as a first treatment.
This trial tests whether adding romiplostim, a drug that helps the body make platelets, to the usual treatment for severe aplastic anemia can improve blood cell counts. It is for people who have not yet started treatment for this condition.
Hear when a new Bone Marrow Failure Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.